celecoxib has been researched along with Cancer of Liver in 54 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 9.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 9.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 7.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 7.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| " We have reported that apoptosis can be restored in human multidrug-resistant (MDR) hepatocellular carcinoma cell lines by celecoxib." | 7.75 | Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. ( Bottini, C; Fantappiè, O; Mazzanti, R; Platini, F; Solazzo, M; Tessitore, L, 2009) |
| "Celecoxib can inhibit the proliferation of different liver cancer cell lines both in vitro and in vivo, and therefore may serve as an important candidate drug for prevention and treatment of hepatocellular carcinoma." | 7.74 | [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells]. ( Lin, QH; Liu, SC; Tang, BD; Zhou, Q, 2007) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 7.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| "Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis." | 6.84 | Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. ( Chen, S; Huang, ZY; Tang, CW; Tong, H; Wei, B; Xie, YM; Zhang, LH; Zhang, MG, 2017) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | 5.51 | Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1. ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL." | 5.36 | Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. ( Hao, C; Ji, B; Liu, Y; Lu, G; Wang, G; Wei, F, 2010) |
| " Postmenopausal metastatic breast cancer patients without previous adjuvant AI treatment received exemestane 25 mg/days plus either celecoxib 400 mg twice daily or placebo." | 5.14 | Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. ( Bachelot, T; Crétin, J; Debled, M; Delozier, T; Falandry, C; Freyer, G; Mauriac, L; Mille, D; Pujade-Lauraine, E; Romestaing, P; You, B, 2009) |
| "Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)." | 5.12 | Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007) |
| "Previous studies have demonstrated that the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib shows efficacy against multiple cancers, including hepatocellular carcinoma." | 3.91 | Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade. ( Chen, L; Deng, X; Hu, J; Li, X; Qiu, Z; Sheng, L; Zhang, C; Zheng, G; Zhou, J, 2019) |
| "Celecoxib, a COX-2 inhibitor and non-steroidal anti-inflammatory drug, can prevent several types of cancer, including hepatocellular carcinoma (HCC)." | 3.80 | Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. ( Chan, HH; Cheng, KH; Chu, TH; Hsu, PI; Hu, TH; Kung, ML; Kuo, HM; Lai, KH; Lin, SW; Liu, LF; Ma, YL; Sun, CK; Tai, MH; Wang, EM; Wen, ZH, 2014) |
| "Sorafenib is a promising treatment for hepatocellular carcinoma (HCC) but recent toxicity concerns suggest that new strategies for its use are needed." | 3.79 | Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. ( Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M, 2013) |
| " We have reported that apoptosis can be restored in human multidrug-resistant (MDR) hepatocellular carcinoma cell lines by celecoxib." | 3.75 | Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line. ( Bottini, C; Fantappiè, O; Mazzanti, R; Platini, F; Solazzo, M; Tessitore, L, 2009) |
| " The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531." | 3.74 | Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008) |
| "Celecoxib can inhibit the proliferation of different liver cancer cell lines both in vitro and in vivo, and therefore may serve as an important candidate drug for prevention and treatment of hepatocellular carcinoma." | 3.74 | [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells]. ( Lin, QH; Liu, SC; Tang, BD; Zhou, Q, 2007) |
| "We previously reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, suppresses growth of human hepatocellular carcinoma (HCC) cells through both COX-2 dependence and independence." | 3.74 | In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. ( Cui, W; Hu, KQ; Hu, SX; Tang, ZY, 2008) |
| "Recurrence of hepatocellular carcinoma (HCC) after transarterial chemoembolisation (TACE) is common due to neoangiogenesis." | 2.84 | Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. ( Chen, S; Huang, ZY; Tang, CW; Tong, H; Wei, B; Xie, YM; Zhang, LH; Zhang, MG, 2017) |
| "Patients with clinical stage II or III rectal cancer were treated with radiotherapy of 44 Gy in 22 fractions." | 2.79 | Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study. ( Chen, HC; Chen, HH; Chen, WT; Chien, CR; Hsiao, CF; Lee, HH; Lin, TC; Lin, TY; Liu, TW; Wang, LW, 2014) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Pancreatic cancer is amongst the most chemoresistant malignancies." | 2.71 | A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. ( Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2005) |
| "MATERIAL AND METHODS We treated hepatocellular carcinoma (HCC) Huh-7 cells and tumor xenograft mice models with celecoxib to test its effects on the tumor." | 1.51 | Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1. ( Dai, H; Ma, R; Pan, L; Zhang, S, 2019) |
| "When HepG2 hepatoma cells were treated with celecoxib, the expression of the genes in de novo sphingolipid biosynthesis and sphingomyelinase pathway was upregulated and cellular ceramide was elevated." | 1.46 | Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization. ( Kim, GT; Kim, JY; Lee, K; Maeng, HJ; Park, TS; Song, JH; Song, YJ, 2017) |
| "Treatment with celecoxib and IFN-α synergistically inhibited cell proliferation in a dose- and time-dependent manner." | 1.42 | Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma. ( Burns, M; Dan, H; Li, Q; Liu, C; Liu, J; Liu, N; Qiu, X; Wang, X; Wu, Q; Xia, M; Xie, H; Yang, D; Zhu, H; Zuo, C, 2015) |
| "Celecoxib is a potent nonsteroidal anti-inflammatory drug that has demonstrated promise in cancer chemoprevention and treatment." | 1.40 | Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line. ( Chen, L; Kan, M; Li, J; Pan, Y; Qiao, P; Shao, D; Wang, Z; Xiao, X, 2014) |
| "In sum, in HA59T hepatoma cells, celecoxib induced a [Ca(2+)]i rise by evoking phospholipase C-dependent Ca(2+) release from the endoplasmic reticulum and Ca(2+) entry via protein kinase C-sensitive store-operated Ca(2+) channels." | 1.40 | Celecoxib-induced increase in cytosolic Ca(2+) levels and apoptosis in HA59T human hepatoma cells. ( Cheng, HH; Cheng, JS; Chi, CC; Chou, CT; Jan, CR; Kuo, CC; Liang, WZ; Liu, SI; Lu, T; Lu, YC; Tseng, LL, 2014) |
| "Etodolac was without influence at concentrations up to 100 μM." | 1.39 | Pharmacological inhibition of beta-catenin in hepatoblastoma cells. ( Armeanu-Ebinger, S; Ellerkamp, V; Fuchs, J; Lieber, J; Nagel, C; Warmann, SW; Wenz, J, 2013) |
| "To evaluate the inhibitory effect and its mechanism of celecoxib combined with capecitabine on the growth of implanted H22 hepatoma in mice." | 1.39 | [Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism]. ( Guo, HQ; Liu, YY; Yang, SJ; Yao, SN; Yao, ZH; Yuan, YD; Zhao, Y, 2013) |
| "Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells." | 1.39 | Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G, 2013) |
| "Human hepatoma cell lines were treated with lipopolysaccharide (LPS) or cyclooxygenase-2 inhibitor, Celecoxib, and in vitro proliferation, apoptosis, and cell cycle progression were assessed." | 1.39 | Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways. ( Bai, L; Mao, ZY; Su, D; Wang, LJ; Zhang, T, 2013) |
| "Celecoxib treatment resulted in significantly altered expression levels of 240 and 403 transcripts in Huh7 and HepG2 cells, respectively." | 1.37 | COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. ( Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Giannitrapani, L; Lampiasi, N; McCubrey, JA; Montalto, G; Sardina, F, 2011) |
| "The vast majority of hepatocellular carcinomas (HCC), however, are resistant to TRAIL." | 1.36 | Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells. ( Hao, C; Ji, B; Liu, Y; Lu, G; Wang, G; Wei, F, 2010) |
| " Our findings suggest that the imbalance between AA and PGE2, characterized by increased AA at a low dosage and decreased PGE2 at a high dosage of celecoxib, was an important indicator of cytotoxicity of celecoxib on H22 cells." | 1.36 | The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway. ( Chen, L; Lv, X; Xiang, D; Xu, Z; Zhang, M; Zhang, X, 2010) |
| "Inhibition of hepatoma cells by cyclooxygenase (COX)-2-dependent and -independent mechanisms has been shown previously." | 1.34 | R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells. ( Behari, J; Leoni, L; Micsenyi, A; Monga, SP; Muller, P; Otruba, W; Sekhon, SS; Thompson, MD; Zeng, G, 2007) |
| "Celecoxib can inhibit proliferation and induce apoptosis of hepatoma cell strains in a dose- and time-dependent manner." | 1.33 | Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. ( Leng, J; Liu, NB; Pan, C; Peng, T; Shen, B; Yao, YY, 2005) |
| "Gallbladder cancer is an asymptomatic disease in the early stage and no therapeutic measure is available except surgical intervention." | 1.33 | [A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine]. ( Hada, M; Horiuchi, T; Shinji, H, 2006) |
| "In the present study, we used a pancreatic cancer model to determine the role of Sp1 in the antitumor activity of celecoxib." | 1.32 | Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. ( Abbruzzese, JL; He, Y; Wang, L; Wei, D; Xie, K; Xiong, HQ, 2004) |
| "11." | 1.31 | Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. ( Bisevac, M; Guski, H; Khodadayan, C; Kilian, M; Müller, JM; Schimke, I; von Seebach, M; Wenger, FA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (51.85) | 29.6817 |
| 2010's | 24 (44.44) | 24.3611 |
| 2020's | 2 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, B | 1 |
| Chen, Z | 1 |
| Zhang, X | 2 |
| Wang, Z | 4 |
| Yao, Y | 1 |
| Wu, X | 1 |
| Qiu, J | 1 |
| Lin, H | 1 |
| Yu, L | 1 |
| Tu, H | 1 |
| Tang, N | 1 |
| Dai, H | 1 |
| Zhang, S | 1 |
| Ma, R | 1 |
| Pan, L | 1 |
| Lee, SH | 1 |
| Moon, HJ | 1 |
| Lee, YS | 1 |
| Kang, CD | 1 |
| Kim, SH | 1 |
| Tong, H | 2 |
| Wei, B | 2 |
| Chen, S | 1 |
| Xie, YM | 1 |
| Zhang, MG | 1 |
| Zhang, LH | 1 |
| Huang, ZY | 1 |
| Tang, CW | 1 |
| Qiu, Z | 1 |
| Zhang, C | 1 |
| Zhou, J | 1 |
| Hu, J | 1 |
| Sheng, L | 1 |
| Li, X | 3 |
| Chen, L | 3 |
| Deng, X | 1 |
| Zheng, G | 1 |
| Jiménez-Luévano, MÁ | 1 |
| Rodríguez-Chávez, JL | 1 |
| Ramírez-Flores, S | 1 |
| Rodríguez-Villa, P | 1 |
| Jiménez-Partida, MÁ | 1 |
| Cervantes-Rodríguez, G | 1 |
| Hernández-Flores, G | 1 |
| Solís-Martínez, R | 1 |
| Bravo-Cuellar, A | 1 |
| Morisaki, T | 1 |
| Umebayashi, M | 1 |
| Kiyota, A | 1 |
| Koya, N | 1 |
| Tanaka, H | 1 |
| Onishi, H | 1 |
| Katano, M | 1 |
| Wang, LJ | 1 |
| Bai, L | 1 |
| Su, D | 1 |
| Zhang, T | 1 |
| Mao, ZY | 1 |
| Cervello, M | 3 |
| Bachvarov, D | 2 |
| Lampiasi, N | 3 |
| Cusimano, A | 2 |
| Azzolina, A | 3 |
| McCubrey, JA | 3 |
| Montalto, G | 3 |
| Yao, ZH | 1 |
| Yuan, YD | 1 |
| Liu, YY | 1 |
| Guo, HQ | 1 |
| Zhao, Y | 1 |
| Yao, SN | 1 |
| Yang, SJ | 1 |
| Wang, LW | 1 |
| Hsiao, CF | 1 |
| Chen, WT | 1 |
| Lee, HH | 1 |
| Lin, TC | 1 |
| Chen, HC | 1 |
| Chen, HH | 1 |
| Chien, CR | 1 |
| Lin, TY | 1 |
| Liu, TW | 1 |
| Sui, W | 1 |
| Zhang, Y | 1 |
| Jia, Q | 1 |
| Wu, L | 1 |
| Zhang, W | 1 |
| Chu, TH | 1 |
| Chan, HH | 1 |
| Kuo, HM | 1 |
| Liu, LF | 1 |
| Hu, TH | 1 |
| Sun, CK | 1 |
| Kung, ML | 1 |
| Lin, SW | 1 |
| Wang, EM | 1 |
| Ma, YL | 1 |
| Cheng, KH | 1 |
| Lai, KH | 1 |
| Wen, ZH | 1 |
| Hsu, PI | 1 |
| Tai, MH | 1 |
| Cheng, HH | 1 |
| Chou, CT | 1 |
| Lu, YC | 1 |
| Lu, T | 1 |
| Chi, CC | 1 |
| Tseng, LL | 1 |
| Liu, SI | 1 |
| Cheng, JS | 1 |
| Kuo, CC | 1 |
| Liang, WZ | 1 |
| Jan, CR | 1 |
| Shao, D | 1 |
| Kan, M | 1 |
| Qiao, P | 1 |
| Pan, Y | 2 |
| Xiao, X | 1 |
| Li, J | 1 |
| Fantappiè, O | 3 |
| Sassoli, C | 1 |
| Tani, A | 1 |
| Nosi, D | 1 |
| Marchetti, S | 1 |
| Formigli, L | 1 |
| Mazzanti, R | 3 |
| Zuo, C | 1 |
| Qiu, X | 1 |
| Liu, N | 1 |
| Yang, D | 1 |
| Xia, M | 1 |
| Liu, J | 2 |
| Wang, X | 1 |
| Zhu, H | 1 |
| Xie, H | 2 |
| Dan, H | 1 |
| Li, Q | 1 |
| Wu, Q | 1 |
| Burns, M | 1 |
| Liu, C | 1 |
| Tang, C | 1 |
| Maeng, HJ | 1 |
| Song, JH | 1 |
| Kim, GT | 1 |
| Song, YJ | 1 |
| Lee, K | 1 |
| Kim, JY | 1 |
| Park, TS | 1 |
| Gao, L | 1 |
| Chai, N | 1 |
| Song, J | 1 |
| Wang, J | 1 |
| Song, Z | 1 |
| Chen, C | 1 |
| Zhao, L | 1 |
| Sun, S | 1 |
| Wu, K | 1 |
| Feitelson, MA | 1 |
| Fan, D | 1 |
| Cui, W | 1 |
| Hu, SX | 1 |
| Tang, ZY | 1 |
| Hu, KQ | 1 |
| Kassam, A | 1 |
| Mandel, K | 1 |
| Falandry, C | 1 |
| Debled, M | 1 |
| Bachelot, T | 1 |
| Delozier, T | 1 |
| Crétin, J | 1 |
| Romestaing, P | 1 |
| Mille, D | 1 |
| You, B | 1 |
| Mauriac, L | 1 |
| Pujade-Lauraine, E | 1 |
| Freyer, G | 1 |
| Platini, F | 2 |
| Bottini, C | 1 |
| Solazzo, M | 2 |
| Tessitore, L | 2 |
| Roy, KR | 1 |
| Reddy, GV | 1 |
| Maitreyi, L | 1 |
| Agarwal, S | 1 |
| Achari, C | 1 |
| Vali, S | 1 |
| Reddanna, P | 1 |
| Lu, G | 1 |
| Liu, Y | 2 |
| Ji, B | 1 |
| Wei, F | 1 |
| Hao, C | 1 |
| Wang, G | 1 |
| Xu, Z | 1 |
| Zhang, M | 1 |
| Lv, X | 1 |
| Xiang, D | 1 |
| Sardina, F | 1 |
| Giannitrapani, L | 1 |
| Liu, A | 1 |
| Li, H | 1 |
| Li, C | 1 |
| Lin, J | 1 |
| Umezawa, K | 1 |
| Ellerkamp, V | 1 |
| Lieber, J | 1 |
| Nagel, C | 1 |
| Wenz, J | 1 |
| Warmann, SW | 1 |
| Fuchs, J | 1 |
| Armeanu-Ebinger, S | 1 |
| Kern, MA | 2 |
| Schubert, D | 1 |
| Sahi, D | 1 |
| Schöneweiss, MM | 1 |
| Moll, I | 1 |
| Haugg, AM | 2 |
| Dienes, HP | 1 |
| Breuhahn, K | 2 |
| Schirmacher, P | 2 |
| Wenger, FA | 2 |
| Kilian, M | 2 |
| Bisevac, M | 1 |
| Khodadayan, C | 1 |
| von Seebach, M | 1 |
| Schimke, I | 2 |
| Guski, H | 1 |
| Müller, JM | 1 |
| Leng, J | 2 |
| Han, C | 1 |
| Demetris, AJ | 1 |
| Michalopoulos, GK | 1 |
| Wu, T | 1 |
| Wei, D | 1 |
| Wang, L | 1 |
| He, Y | 1 |
| Xiong, HQ | 1 |
| Abbruzzese, JL | 1 |
| Xie, K | 1 |
| Graepler, F | 1 |
| Gregor, M | 1 |
| Lauer, UM | 1 |
| Maiello, E | 1 |
| Gebbia, V | 1 |
| Giuliani, F | 1 |
| Paoletti, G | 1 |
| Gebbia, N | 1 |
| Borsellino, N | 1 |
| Cartenì, G | 1 |
| Pezzella, G | 1 |
| Manzione, L | 1 |
| Romito, S | 1 |
| Lopez, M | 1 |
| Colucci, G | 1 |
| Gregor, JI | 1 |
| Heukamp, I | 1 |
| Kiewert, C | 1 |
| Kristiansen, G | 1 |
| Walz, MK | 1 |
| Jacobi, CA | 1 |
| Márquez-Rosado, L | 1 |
| Trejo-Solís, MC | 1 |
| García-Cuéllar, CM | 1 |
| Villa-Treviño, S | 1 |
| Malka, D | 1 |
| Pacault, V | 1 |
| De Baere, T | 1 |
| Ducreux, M | 1 |
| Boige, V | 1 |
| El-Rayes, BF | 1 |
| Zalupski, MM | 1 |
| Shields, AF | 1 |
| Ferris, AM | 1 |
| Vaishampayan, U | 1 |
| Heilbrun, LK | 1 |
| Venkatramanamoorthy, R | 1 |
| Adsay, V | 1 |
| Philip, PA | 1 |
| Liu, NB | 1 |
| Peng, T | 1 |
| Pan, C | 1 |
| Yao, YY | 1 |
| Shen, B | 1 |
| Hada, M | 1 |
| Horiuchi, T | 1 |
| Shinji, H | 1 |
| Zuo, CH | 1 |
| Li, ZR | 1 |
| Zhou, X | 1 |
| Ouyang, YZ | 1 |
| Zhou, ZY | 1 |
| Zeng, L | 1 |
| Koch, AF | 1 |
| Schilling, T | 1 |
| Walczak, H | 1 |
| Fleischer, B | 1 |
| Trautwein, C | 1 |
| Michalski, C | 1 |
| Schulze-Bergkamen, H | 1 |
| Friess, H | 1 |
| Stremmel, W | 1 |
| Krammer, PH | 1 |
| Müller, M | 1 |
| Song, HJ | 1 |
| Kim, YS | 2 |
| Han, CH | 1 |
| Jang, JY | 1 |
| Kim, JH | 1 |
| Cheon, YK | 1 |
| Moon, JH | 1 |
| Cho, YD | 1 |
| Shim, CS | 1 |
| Kwon, KH | 1 |
| Kim, BS | 1 |
| André, T | 1 |
| Tournigand, C | 1 |
| Mineur, L | 1 |
| Fellague-Chebra, R | 1 |
| Flesch, M | 1 |
| Mabro, M | 1 |
| Hebbar, M | 1 |
| Postel Vinay, S | 1 |
| Bidard, FC | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Behari, J | 1 |
| Zeng, G | 1 |
| Otruba, W | 1 |
| Thompson, MD | 1 |
| Muller, P | 1 |
| Micsenyi, A | 1 |
| Sekhon, SS | 1 |
| Leoni, L | 1 |
| Monga, SP | 1 |
| Lasagna, N | 1 |
| Schönthal, AH | 1 |
| Tang, BD | 1 |
| Zhou, Q | 1 |
| Lin, QH | 1 |
| Liu, SC | 1 |
| Bolieva, LZ | 1 |
| Dzhioev, FK | 1 |
| Kakabadze, SA | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| de Heer, P | 1 |
| Sandel, MH | 1 |
| Guertens, G | 1 |
| de Boeck, G | 1 |
| Koudijs, MM | 1 |
| Nagelkerke, JF | 1 |
| Junggeburt, JM | 1 |
| de Bruijn, EA | 1 |
| van de Velde, CJ | 1 |
| Kuppen, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Celebrex and Metformin for Postoperative Hepatocellular Carcinoma[NCT03184493] | Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-02 | Recruiting | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553] | Phase 2 | 0 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for celecoxib and Cancer of Liver
| Article | Year |
|---|---|
[Anti-angiogenic therapy for gastrointestinal tumours].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2005 |
7 trials available for celecoxib and Cancer of Liver
| Article | Year |
|---|---|
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2017 |
Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chemoradioth | 2014 |
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Aromatase I | 2009 |
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2005 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas | 2007 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
46 other studies available for celecoxib and Cancer of Liver
| Article | Year |
|---|---|
2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Celecoxib; Dinoprostone; Gastroin | 2023 |
Celecoxib Inhibits Hepatocellular Carcinoma Cell Growth and Migration by Targeting PNO1.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Movement; Cell Prol | 2019 |
Potentiation of TRAIL‑induced cell death by nonsteroidal anti‑inflammatory drug in human hepatocellular carcinoma cells through the ER stress‑dependent autophagy pathway.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2020 |
Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cycloo | 2019 |
Treatment of hepatocarcinoma with celecoxib and pentoxifylline: a case report
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ce | 2018 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellu | 2013 |
Proinflammatory conditions promote hepatocellular carcinoma onset and progression via activation of Wnt and EGFR signaling pathways.
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Disease Progres | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2013 |
[Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism].
Topics: Animals; Capecitabine; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; | 2013 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell | 2014 |
Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Cyc | 2014 |
Celecoxib-induced increase in cytosolic Ca(2+) levels and apoptosis in HA59T human hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; C | 2014 |
Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Ca | 2014 |
Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma, Hepatocellula | 2015 |
Interferon-α and cyclooxygenase-2 inhibitor cooperatively mediates TRAIL-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspases; Celecoxib; Cell Line | 2015 |
Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celecoxib; Chemoembolizat | 2015 |
Celecoxib-mediated activation of endoplasmic reticulum stress induces de novo ceramide biosynthesis and apoptosis in hepatoma HepG2 cells mobilization.
Topics: Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Survival; Ceramides; Endopla | 2017 |
Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspase Inhibitors; Caspases; Celecoxib; Ce | 2009 |
In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Topics: Acetylation; alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cy | 2008 |
Metastatic hepatic epithelioid hemangioendothelioma in a teenage girl.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Ce | 2008 |
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Celec | 2009 |
Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel | 2010 |
Synergistic effect of celecoxib on TRAIL-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Campto | 2010 |
The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
Topics: Animals; Arachidonic Acid; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular | 2010 |
COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Survival; Cycloo | 2011 |
Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxyge | 2011 |
The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Hepatocellular; Celecoxib; | 2012 |
Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Topics: Antineoplastic Agents; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Celecoxib; Cell Line, | 2013 |
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; Carr | 2002 |
Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cricetinae; Hydroxyurea; Lipid Peroxida | 2002 |
Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Division; Cyclooxygenas | 2003 |
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Topics: Adenocarcinoma; Animals; Celecoxib; Cyclooxygenase Inhibitors; Electrophoretic Mobility Shift Assay; | 2004 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoproston | 2005 |
Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Liver Neoplasms; Liver Neoplasms, Experimental; Male; | 2005 |
Antitumoral effect of celecoxib in hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Celecoxib; Cyclooxygenase Inhibitors; Humans; Liver Neoplasms; Male | 2005 |
Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Line, Tumor; C | 2005 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration | 2006 |
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Topics: Angiopoietin-2; Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; C | 2006 |
Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase | 2006 |
[A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Celeco | 2006 |
R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, | 2007 |
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Prot | 2007 |
Induction of apoptosis by celecoxib in cell culture: an uncertain role for cyclooxygenase-2.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Enzyme Inductio | 2007 |
[Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on the proliferation of hepatocellular carcinoma cells].
Topics: Animals; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase | 2007 |
Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Celecoxib; Dieth | 2007 |
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colo | 2008 |